Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roderick L Beijersbergen

Showing results (31-40 of 98) with videos related to

Pageof 10
Sort By:
Journal of Hepatology|July 22, 2018
Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancerCun Wang, Haojie Jin, Dongmei Gao, et al.
Cell Research|March 7, 2018
A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinomaCun Wang, Haojie Jin, Dongmei Gao, et al.
Cancer Research|November 18, 2008
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235Pieter J A Eichhorn, Magüi Gili, Maurizio Scaltriti, et al.
Molecular and Cellular Biology|June 19, 2013
The corepressor CTBP2 is a coactivator of retinoic acid receptor/retinoid X receptor in retinoic acid signalingPrashanth Kumar Bajpe, Guus J J E Heynen, Lorenza Mittempergher, et al.
European Journal of Immunology|October 18, 2019
High-throughput compound screen reveals mTOR inhibitors as potential therapeutics to reduce (auto)antibody production by human plasma cellsPaul Tuijnenburg, Daan J Aan de Kerk, Machiel H Jansen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2009
Candidate biomarkers of response to an experimental cancer drug identified through a large-scale RNA interference genetic screenJasper Mullenders, Wolfgang von der Saal, Miranda M W van Dongen, et al.
Life Science Alliance|August 22, 2020
The RECQL helicase prevents replication fork collapse during replication stressBente Benedict, Marit Ae van Bueren, Frank Pa van Gemert, et al.
Genome Medicine|November 29, 2018
A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancersTonći Šuštić, Sake van Wageningen, Evert Bosdriesz, et al.
Nucleic Acids Research|July 2, 2024
Chromatin context-dependent effects of epigenetic drugs on CRISPR-Cas9 editingRuben Schep, Max Trauernicht, Xabier Vergara, et al.
Genome Medicine|February 11, 2021
Correction to: A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancersTonći Šuštić, Sake van Wageningen, Evert Bosdriesz, et al.
Pageof 10

Showing results (31-40 of 98) with videos related to

Sort By:
Pageof 10
Journal of Hepatology|July 22, 2018
Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancerCun Wang, Haojie Jin, Dongmei Gao, et al.
Cell Research|March 7, 2018
A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinomaCun Wang, Haojie Jin, Dongmei Gao, et al.
Cancer Research|November 18, 2008
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235Pieter J A Eichhorn, Magüi Gili, Maurizio Scaltriti, et al.
Molecular and Cellular Biology|June 19, 2013
The corepressor CTBP2 is a coactivator of retinoic acid receptor/retinoid X receptor in retinoic acid signalingPrashanth Kumar Bajpe, Guus J J E Heynen, Lorenza Mittempergher, et al.
European Journal of Immunology|October 18, 2019
High-throughput compound screen reveals mTOR inhibitors as potential therapeutics to reduce (auto)antibody production by human plasma cellsPaul Tuijnenburg, Daan J Aan de Kerk, Machiel H Jansen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2009
Candidate biomarkers of response to an experimental cancer drug identified through a large-scale RNA interference genetic screenJasper Mullenders, Wolfgang von der Saal, Miranda M W van Dongen, et al.
Life Science Alliance|August 22, 2020
The RECQL helicase prevents replication fork collapse during replication stressBente Benedict, Marit Ae van Bueren, Frank Pa van Gemert, et al.
Genome Medicine|November 29, 2018
A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancersTonći Šuštić, Sake van Wageningen, Evert Bosdriesz, et al.
Nucleic Acids Research|July 2, 2024
Chromatin context-dependent effects of epigenetic drugs on CRISPR-Cas9 editingRuben Schep, Max Trauernicht, Xabier Vergara, et al.
Genome Medicine|February 11, 2021
Correction to: A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancersTonći Šuštić, Sake van Wageningen, Evert Bosdriesz, et al.
Pageof 10